Taken together, our results suggest that the ability of EGFr TKIs to reverse the inhibitory effects of EGF on calcium‐dependent chloride secretion, and to potentiate secretory responses to CCh, could contribute to the diarrheal side‐effects of these agents. The gene discussed is EGF; the disease is columnar cell hyperplasia of the breast.